Back to Results

Cardio Diagnostics Holdings Inc (CDIO)

Cardio Diagnostics Holdings, Inc. is a healthcare company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. Its product lineup includes Epi+Gen CHD, a blood test designed to assess three-year symptomatic coronary heart disease risk, and PrecisionCHD, an integrated epigenetic-genetic test for detecting coronary heart disease. The company also provides Actionable Clinical Intelligence, a platform intended to give clinicians epigenetic and genetic insights to support chronic care management. In addition, it offers CardioInnovate360, a research-use-only solution for biopharmaceutical discovery and validation in cardiovascular disease, and HeartRisk, a SaaS-based cardiovascular risk intelligence platform. Cardio Diagnostics serves telemedicine providers, provider organizations, and employer organizations. The company was founded in 2017 and is headquartered in Chicago, Illinois.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CDIO
$2.94
45.3% Upside
Undervalued
Not available
Not available
Fair
0.0%
November 6, 2026
0.8x
413.7x
5.978 M
761.128 K
5.8%
95.9%
-1.4
90.0%
Valuation • Fair Value

Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) Fair Value by Valuation Model

Review the available estimates for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.94

Estimated upside of 45.3% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.94

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

14.45 K

Current operating scale indicator.

Revenue Forecast

25 M

Forward revenue estimate.

EBITDA

-6.084 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-3.48

No elevated caution signal from this screen.

Altman Z-Score

-1.4

Lower score that deserves closer risk review.

FCF / Net Income

90.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 6, 2026

Days to Earnings

49

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) Stock Forecast & Technical Outlook

Review Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) Stock FAQ

Data-supported answers about Cardio Diagnostics Holdings Inc (NASDAQ-CDIO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.94
Estimated upside 45.3%
Valuation Rating
Undervalued
Estimated upside of 45.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is $2.94. This implies an estimated upside of 45.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 45.3% versus the current market price.

The current financial health read for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is November 6, 2026.

The latest available data indicates no current dividend yield for Cardio Diagnostics Holdings Inc (NASDAQ-CDIO).

The current market capitalization listed for Cardio Diagnostics Holdings Inc is 5.978 M.

The current enterprise value listed for Cardio Diagnostics Holdings Inc is 761.128 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cardio Diagnostics Holdings Inc is NASDAQ-CDIO, and the stock is listed on NASDAQ.

Cardio Diagnostics Holdings Inc (NASDAQ-CDIO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cardio Diagnostics Holdings Inc is 5.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cardio Diagnostics Holdings Inc is 95.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B